



## NEWS RELEASE

### **FSD Pharma to Present at the H.C. Wainwright 2<sup>nd</sup> Annual Psychedelics Virtual Conference on December 6<sup>th</sup>**

**Toronto, December 3, 2021** – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“**FSD Pharma**” or the “**Company**”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2<sup>nd</sup> Annual Virtual Psychedelics Conference to be held on December 6, 2021. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET and accessible to view on the investor relations section of FSD’s website at <https://ir.fsdpharma.com/news-events/events-presentations>.

In addition, members of FSD Pharma’s management team will be available for one-on-one investor meetings during the conference.

For more information about the conference, or to schedule a one-on-one meeting with FSD's management team, please contact KCSA Strategic Communications at [FSDPharma@kcsa.com](mailto:FSDPharma@kcsa.com) or an H.C. Wainwright representative directly.

#### **About FSD Pharma**

FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”) is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Through the Company’s wholly owned subsidiary, Lucid, the Company is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.

#### **For further information:**

Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc.

Email: [Zsaeed@fsdpharma.com](mailto:Zsaeed@fsdpharma.com)

Telephone: (416) 854-8884

Investor Relations: Email: [skilmer@fsdpharma.com](mailto:skilmer@fsdpharma.com), Website: [www.fsdpharma.com](http://www.fsdpharma.com)